MedTrace Logo

Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

NCT01208545 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2010-09-24

No results posted yet for this study

Summary

The study hypothesis is that changes in serially obtained nerve conduction study data obtained every 3-4 weeks in cancer patients receiving chemotherapy can be used to predict the development of a clinically significant / disabling drug induced neuropathy six and twelve months following the start of treatment. Patients with breast cancer, colon cancer, gastroesophageal cancer, and non-Hodgkins lymphoma will be enrolled. Six lower extremity nerves--three in each leg--will be electrically stimulated and their responses recorded at three to four week intervals coinciding with patient's scheduled chemotherapy.

Conditions

  • Chemotherapy
  • Nerve Degeneration
  • Nerve Conduction

Sponsors & Collaborators

  • NeuroMetrix, Inc.

    lead INDUSTRY

Principal Investigators

  • Eugene A Lesser, D.O. · NeuroMetrix, Inc.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208545 on ClinicalTrials.gov